Prescient Therapeutics
ASX:PTXMelbourne, Australia· Est.
Australian early‑stage oncology biotech leveraging a GGT‑1 inhibitor and novel CAR‑T platforms to address unmet‑need cancers.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian early‑stage oncology biotech leveraging a GGT‑1 inhibitor and novel CAR‑T platforms to address unmet‑need cancers.
Oncology
Technology Platform
PTX‑100 is a GGT‑1 inhibitor that blocks RAS prenylation; CellPryme and OmniCAR are modular platforms designed to enhance CAR‑T efficacy, safety, and antigen flexibility.
Opportunities
Successful Phase 2 data could unlock fast‑track approval and partnership deals; the cell‑therapy platforms position Prescient for broader immunotherapy collaborations.
Risk Factors
Clinical trial failure, regulatory delays, and the need for substantial funding to advance late‑stage development pose significant risks.
Competitive Landscape
PTX‑100 is unique as the only GGT‑1 inhibitor in clinical testing, while CellPryme and OmniCAR differentiate Prescient from other CAR‑T developers by offering modular, safety‑enhanced platforms.